Loading stock data...

Bacil Pharma Limited

BSE: BACPHAR

BSE
41.50 0.00 (0.00%)

Prev Close

41.5

Open Price

43.68

Volume

5,600

Today Low / High

41.5 / 45.75

52 WK Low / High

34.48 / 55.44

Range

39 - 44

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 41.5, reflecting a change of 0 (0%). The expected target range on the BSE is 39 - 44. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

15 Apr 43.68 -4.99%
04 Apr 45.90 -4.84%
03 Apr 45.95 -0.37%
02 Apr 43.61 0.48%
01 Apr 43.99 1.16%
28 Mar 42.10 0.93%
27 Mar 40.03 4.67%
26 Mar 40.00 0.08%
25 Mar 41.50 -0.46%
24 Mar 42.58 -6.06%
21 Mar 40.50 0.15%
20 Mar 41.50 -6.92%

Bacil Pharma Limited Graph

Bacil Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Bacil Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 41.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 41.50 41.92 37.72 - 46.11
42.33 33.86 - 50.80
42.75 29.92 - 55.57
Bearish Scenario 41.50 41.09 36.98 - 45.19
40.67 32.54 - 48.80
40.26 28.18 - 52.33

Overview of Bacil Pharma Limited

ISIN

INE711D01018

Industry

Medical - Pharmaceuticals

Vol.Avg

26,917

Market Cap

244,435,000

Last Dividend

0

Official Website

Visit Website

IPO Date

2000-01-03

DCF Diff

41.60

DCF

0

Financial Ratios Every Investor Needs

Stock Rating Details for BACPHAR

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2024-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.00 Cr 0.00 Cr -0.19 Cr -0.06 Cr -0.10 -0.06 Cr 0.0000
2023-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.00 Cr 0.01 Cr -0.18 Cr -0.10 Cr -0.17 -0.10 Cr 0.0000
2022-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.00 Cr 0.02 Cr -0.16 Cr -3.86 Cr -6.55 -3.86 Cr 0.0000
2021-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.01 Cr 0.01 Cr -0.17 Cr -0.24 Cr -0.41 -0.23 Cr 0.0000
2020-03-31 0.00 Cr 0.01 Cr -0.01 Cr 0.0000 0.01 Cr 0.02 Cr -0.20 Cr -0.32 Cr -0.54 -0.31 Cr 0.0000

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2024-03-31 0.04 Cr 1.33 Cr 0.11 Cr 1.2132 Cr 0.10 Cr 0.06 Cr 0.00 Cr 0.01 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.1129 Cr
2023-03-31 0.03 Cr 1.13 Cr 0.03 Cr 1.0994 Cr 0.02 Cr -0.01 Cr 0.00 Cr 0.01 Cr 0.00 Cr 0.00 Cr 0.04 Cr 0.0279 Cr
2022-03-31 0.23 Cr 1.27 Cr 0.05 Cr 1.2244 Cr 0.03 Cr -0.20 Cr 0.00 Cr 0.01 Cr 0.00 Cr 0.00 Cr 0.16 Cr 0.0472 Cr
2021-03-31 0.10 Cr 4.09 Cr 2.70 Cr 1.3913 Cr 0.18 Cr 0.08 Cr 0.00 Cr 0.01 Cr 2.50 Cr 0.00 Cr 1.16 Cr 2.6970 Cr
2020-03-31 0.04 Cr 4.11 Cr 2.72 Cr 1.3866 Cr 0.17 Cr 0.13 Cr 0.00 Cr 0.02 Cr 0.00 Cr 0.00 Cr 1.10 Cr 2.7185 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2024-03-31 -0.0512 Cr 0.0489 Cr 0.0150 Cr -0.0513 Cr 0.0127 Cr 0.0415 Cr 0.0000 Cr -0.0590 Cr -0.0628 Cr 0.0000 Cr 0.0000 Cr
2023-03-31 -0.1475 Cr -0.1163 Cr 0.0628 Cr -0.1475 Cr -0.2009 Cr 0.0288 Cr 0.0000 Cr -0.1019 Cr 0.0503 Cr 0.0000 Cr 0.0000 Cr
2022-03-31 -4.0089 Cr 3.8122 Cr 0.3275 Cr -4.0089 Cr 0.1307 Cr 0.2298 Cr 0.0000 Cr -3.8600 Cr 0.3275 Cr 0.0000 Cr 0.0000 Cr
2021-03-31 -0.3980 Cr 0.5278 Cr -0.0733 Cr -0.3980 Cr 0.0565 Cr 0.0990 Cr 0.0000 Cr -0.2392 Cr -0.0665 Cr 0.0000 Cr 0.0000 Cr
2020-03-31 -0.3783 Cr 0.3869 Cr -0.0556 Cr -0.3783 Cr -0.0470 Cr 0.0426 Cr 0.0000 Cr -0.3152 Cr 0.0738 Cr 0.0000 Cr 0.0000 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2024-12-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 0.00 Cr -0.06 Cr -0.10 -0.06 Cr 0.0000
2024-09-30 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 -0.07 Cr 0.48 Cr 0.82 -0.07 Cr 0.0000
2024-06-30 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 -0.04 Cr -0.03 Cr -0.06 -0.04 Cr 0.0000
2024-03-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 -0.06 Cr -0.04 Cr -0.07 0.07 Cr 0.0000
2023-12-31 0.00 Cr 0.00 Cr 0.00 Cr 0.0000 -0.06 Cr -0.02 Cr -0.04 -0.06 Cr 0.0000

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2024-09-30 0.12 Cr 0.00 Cr 0.12 Cr 0.00 Cr 0.00 Cr 0.15 Cr 0.00 Cr 1.86 Cr 0.17 Cr
2024-03-31 0.04 Cr 0.00 Cr 0.04 Cr 0.00 Cr 0.00 Cr 0.05 Cr 0.01 Cr 1.33 Cr 0.11 Cr
2023-12-31 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-09-30 0.03 Cr 0.33 Cr 0.35 Cr 0.00 Cr 0.00 Cr 0.38 Cr 0.01 Cr 1.28 Cr 0.04 Cr
2023-06-30 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2023-12-31 -0.02 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.03 Cr 0.03 Cr 0.00 Cr 0.00 Cr
2023-09-30 -0.01 Cr -0.01 Cr 0.00 Cr 0.00 Cr -0.01 Cr 0.03 Cr 0.04 Cr 0.00 Cr -0.01 Cr
2023-06-30 0.02 Cr 0.02 Cr 0.00 Cr 0.00 Cr -0.01 Cr 0.02 Cr 0.03 Cr 0.00 Cr 0.02 Cr
2023-03-31 -0.08 Cr -0.08 Cr 0.00 Cr 0.00 Cr -0.08 Cr 0.03 Cr 0.10 Cr 0.00 Cr -0.08 Cr
2022-12-31 -0.04 Cr -0.04 Cr 0.00 Cr 0.00 Cr -0.08 Cr -0.04 Cr 0.04 Cr 0.00 Cr -0.04 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹795.30 ₹95,148,896,700.00 ₹151,791.00

Key Executives

Executive Director
Mr. Prakash Bhoorchand Shah

Gender: male

Year Born: 1956

Manager
Mr. Ganpat Dhondu Salekar

Gender: male

Year Born: 1975

Company Secretary & Compliance Officer
Ms. Bhavana Tak

Gender: female

Year Born:

FAQs about Bacil Pharma Limited

Who is the CEO of the company?

The CEO is Mr. Ganpat Dhondu Salekar.

What is the current market price of the stock?

The current price is ₹41.50.

What is the 52-week price range?

The range is ₹34.48-55.44.

What is the market capitalization of the company?

The market capitalization is ₹24.44 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 73.35.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Bacil Pharma Limited (ISIN: INE711D01018) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹24.44 crores and an average daily volume of 26,917 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack